190 related articles for article (PubMed ID: 37116624)
1. Effects of Plant-Based Protein Consumption on Kidney Function and Mineral Bone Disorder Outcomes in Adults With Stage 3-5 Chronic Kidney Disease: A Systematic Review.
Burstad KM; Cladis DP; Wiese GN; Butler M; Hill Gallant KM
J Ren Nutr; 2023 Nov; 33(6):717-730. PubMed ID: 37116624
[TBL] [Abstract][Full Text] [Related]
2. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
4. Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease.
Stremke ER; Biruete A; Hill Gallant KM
Curr Osteoporos Rep; 2020 Jun; 18(3):247-253. PubMed ID: 32240477
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of randomized controlled trials of tonifying kidney and strengthen bone therapy on nondialysis patients with chronic kidney disease-mineral and bone disorder.
Wu G; Li L; Wu Z
Medicine (Baltimore); 2023 Jun; 102(25):e34044. PubMed ID: 37352066
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.
Meza K; Biswas S; Zhu YS; Gajjar A; Perelstein E; Kumar J; Akchurin O
Pediatr Nephrol; 2021 Jun; 36(6):1579-1587. PubMed ID: 33387018
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. The Importance of Phosphate Control in Chronic Kidney Disease.
Tsuchiya K; Akihisa T
Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
10. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
11. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
12. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.
Chuang SH; Wong HC; Vathsala A; Lee E; How PP
Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.
Yeung WG; Palmer SC; Strippoli GFM; Talbot B; Shah N; Hawley CM; Toussaint ND; Badve SV
Am J Kidney Dis; 2023 Nov; 82(5):543-558. PubMed ID: 37356648
[TBL] [Abstract][Full Text] [Related]
15. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
16. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
17. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
18. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
Yamada S; Nakano T
J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
[TBL] [Abstract][Full Text] [Related]
20. Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway.
Shen J; Liu Y; Wang Q; Chen H; Hu Y; Guo X; Liu X; Li Y
J Ethnopharmacol; 2023 Oct; 314():116590. PubMed ID: 37207881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
